Chhatar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chhatar has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Arvind Ingle
Laboratory Animal Facility, Animal Oncology Group, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre Navi Mumbai, India
1 shared publication Astha Sharma
Medicinal Chemistry and Cell Biology Laboratory Department of Chemical Sciences Tata Institute of Fundamental Research Homi Bhabha Road Mumbai Maharashtra 400005 India
1 shared publication- Jyoti Kode
Kode Lab, Tumor Immunology & Immunotherapy Group, Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India
1 shared publication Madan Barkume
Anti-Cancer Drug Screening Facility (ACDSF), ACTREC Tata Memorial Centre, Kharghar Navi Mumbai 410210 India
1 shared publication- Malay Patra
Tata Institute of Fundamental Research Homi Bhabha Road
1 shared publication Manasi Nagare
Tumor Immunology & Immunotherapy Group (Kode lab) Advanced Centre for Treatment Research & Education in Cancer (ACTREC) Tata Memorial Centre, Kharghar Navi Mumbai 410210 India
1 shared publication
Latest Publications
- 30 June 2022
- Published by Wiley in Chemistry – A European Journal
- Vol. 28 (46) , e202201259
A Rationally Designed Bimetallic Platinum (II)‐Ferrocene Antitumor Agent Induces Non‐Apoptotic Cell Death and Exertsin VivoEfficacy
Despite phenomenal clinical success, the efficacy of platinum anticancer drugs is often compromised due to inherent and acquired drug resistant phenotypes in cancers. To circumvent this issue, we designed two heterobimetallic platinum (II)‐ferrocene hybrids that display multi‐pronged anticancer action. In cancer cells, our best compound,2, platinates DNA, produces reactive oxygen species, and has nucleus, mitochondria, and endoplasmic reticulum as potential targets. The multi‐modal mechanism of action of these hybrid agents lead to non‐apoptotic cell death induction which enables circumventing apoptosis resistance and significant improvement in platinum cross resistance profile. Finally, in addition to describing detail mechanistic insights, we also assessed its stability in plasma and demonstrate anticancer efficacy in an in vivo A2780 xenograft model. Strikingly, compared to oxaliplatin, our compound displays better tolerability, safety profile and efficacy in vivo.
- 30 June 2022
- Published by Wiley in Chemistry – A European Journal
- Vol. 28 (46) , e202201259
A Rationally Designed Bimetallic Platinum (II)‐Ferrocene Antitumor Agent Induces Non‐Apoptotic Cell Death and Exertsin VivoEfficacy
Despite phenomenal clinical success, the efficacy of platinum anticancer drugs is often compromised due to inherent and acquired drug resistant phenotypes in cancers. To circumvent this issue, we designed two heterobimetallic platinum (II)‐ferrocene hybrids that display multi‐pronged anticancer action. In cancer cells, our best compound,2, platinates DNA, produces reactive oxygen species, and has nucleus, mitochondria, and endoplasmic reticulum as potential targets. The multi‐modal mechanism of action of these hybrid agents lead to non‐apoptotic cell death induction which enables circumventing apoptosis resistance and significant improvement in platinum cross resistance profile. Finally, in addition to describing detail mechanistic insights, we also assessed its stability in plasma and demonstrate anticancer efficacy in an in vivo A2780 xenograft model. Strikingly, compared to oxaliplatin, our compound displays better tolerability, safety profile and efficacy in vivo.